Pre-treatment with CD37 Antibody Enhances Amount of Betalutin to NHL Tumors, Study Finds
News
Preliminary trial results show that pre-treatment with the antibody lilotomab may increase the amount of Nordic Nanovector‘s investigational therapy Betalutin that reaches tumor lesions in patients with non-Hodgkin’s lymphoma (NHL). Representatives from ... Read more